UNLIMITED TURBO LONG - MODERNA | Market Closed - Euronext Paris 12:14:35 2024-06-17 pm EDT | ||
| 8.71 EUR | -0.68% |
|
| Current month | -2.12% | ||
| 1 month | +13.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 8.71 | -0.68% |
| 24-06-14 | 8.77 | -6.10% |
| 24-06-13 | 9.34 | -1.27% |
| 24-06-12 | 9.46 | -1.46% |
| 24-06-11 | 9.6 | +1.27% |
Real-time Euronext Paris
Last update June 17, 2024 at 12:14 pm EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| I43MB | |
| ISIN | NLBNPNL2JVU5 |
| Date issued | 2023-10-31 |
| Strike | 57.59 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.72 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.4 € |
|---|---|
| Lowest since issue | 2.02 € |
| Spread | 0.02 € |
| Spread % | 0.23% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- I43MB Certificat
